| Literature DB >> 35052199 |
Lesley Meng1, Krzysztof Laudanski2, Mariana Restrepo3, Ann Huffenberger4, Christian Terwiesch5.
Abstract
We estimated the harm related to medication delivery delays across 12,474 medication administration instances in an intensive care unit using retrospective data in a large urban academic medical center between 2012 and 2015. We leveraged an instrumental variables (IV) approach that addresses unobserved confounds in this setting. We focused on nurse shift changes as disruptors of timely medication (vasodilators, antipyretics, and bronchodilators) delivery to estimate the impact of delay. The average delay around a nurse shift change was 60.8 min (p < 0.001) for antipyretics, 39.5 min (p < 0.001) for bronchodilators, and 57.1 min (p < 0.001) for vasodilators. This delay can increase the odds of developing a fever by 32.94%, tachypnea by 79.5%, and hypertension by 134%, respectively. Compared to estimates generated by a naïve regression approach, our IV estimates tend to be higher, suggesting the existence of a bias from providers prioritizing more critical patients.Entities:
Keywords: critical care patient management; empirical analysis; instrumental variables; intensive care unit operations; medication delay; patient health measurement; quality of health care
Year: 2021 PMID: 35052199 PMCID: PMC8774917 DOI: 10.3390/healthcare10010035
Source DB: PubMed Journal: Healthcare (Basel) ISSN: 2227-9032
Medication names included in each medication group.
| Medication Group | Medication Names Included in Group |
|---|---|
| Antipyretics | Acetaminophen, Acetaminophen Suppository, Acetaminophen Oral Liquid, Acetaminophen Tablet. |
| Inhalers | Albuterol Inhaler, Albuterol-Ipratropium Inhaler, Ipratropium-Albuterol Nebulization, Beclomethasone 80 micrograms Inhaler, Ipratropium Inhaler, Levalbuterol 0.63 mg/3 mL Solution, Tiotropium Bromide. |
| Vasodilators | Hydralazine, Hydralazine Injection. |
Control variables included in regression models.
| Control Group | Controls |
|---|---|
| Unit/Hospital Level | Hospital |
| Unit | |
| Patient/Medication Level | Patient Gender |
| Patient Age | |
| Patient Complexity | |
| Primary Diagnosis Code | |
| Total ICU Stay Elapsed | |
| Pre-Order Health State | |
| Time-Related Controls | Year Medication Ordered |
| Month Medication Ordered | |
| Hour Medication Ordered |
Figure 1Flow chart detailing dataset inclusion criteria.
Study sample summary statistics.
| Measure | Summary Statistic (units) |
|---|---|
| Patient Age | 61.4 ± 15.8 ( |
| Patient Gender | 43% Female |
| ICU Length of Stay | 6 ± 7 days ( |
| Discharge Destinations | 59% discharge to home; 33% discharge to a long-term care facility or nursing home; 8% of patients expire during the stay. |
Figure 2Box plots showing the distribution of observed delays across medication groups. The box plot shows the median and quartiles of observed delays (in minutes) of antipyretics, inhalers, and vasodilators. The mean delays (standard deviation) for these three groups are: 61.3 min (114 min) for antipyretics, 73.8 min (133 min) for inhalers, and 45.1 min (72 min) for vasodilators. This figure is truncated for clarity; the y-axis is truncated to show delays between 0 and 200 min.
Table of first-stage regression results for medication delays in antipyretics, inhalers, and vasodilators.
| Model (1) | Model (2) | Model (3) | |
|---|---|---|---|
| Shift Change IV | 60.81 *** (3.14) | 39.51 *** (3.91) | 57.11 *** (2.06) |
| Other Pt Delay IV (mins) | 0.56 *** (0.01) | 0.76 *** (0.02) | 0.21 *** (0.01) |
| Pre-Vital Sign Controls | Yes | Yes | Yes |
| Unit Controls | Yes | Yes | Yes |
| Patient Controls | Yes | Yes | Yes |
| Time Controls | Yes | Yes | Yes |
| Observations | 14,474 | 14,474 | 14,474 |
| Adjusted R2 | 0.25 | 0.08 | 0.12 |
| F-Statistic | 1752.7 *** | 1117.6 *** | 1015.0 *** |
*** p < 0.001. Note: F-Statistic and significance from ANOVA F-tests comparing models with our instruments included with models without instruments. The numbers represent the coefficient estimates; the numbers in parentheses represent standard errors on these estimates. Statistical significance is shown using asterisks.
Table of second stage regression results with and without instrumental variables showing the impact of medication delays on the patient health states as measured by vital signs (for antipyretics, inhalers, and vasodilators).
| Antipyretic Delay | Inhaler Delay | Vasodilator Delay | ||||
|---|---|---|---|---|---|---|
| Model (4) | Model (5) | Model (6) | Model (7) | Model (8) | Model (9) | |
| Medication Delay (min) | 0.54% * (0.22%) | 0.10%(0.08%) | 1.06% * (0.45%) | −0.05% (0.13%) | 2.99% *** (0.70%) | 1.05% *** (0.27%) |
| Year | −8.79% * (4.45%) | −9.14% * (4.44%) | −4.83% (2.78%) | −4.91% (2.78%) | 1.61%(2.92%) | 1.65%(2.91%) |
| Month | −2.44% * (1.22%) | −2.47% * (1.22%) | −1.22% (0.78%) | −1.16% (0.78%) | −0.05% (0.84%) | −0.06% (0.84%) |
| Hour | 0.23%(0.49%) | 0.29%(0.49%) | 0.04%(0.33%) | 0.05%(0.33%) | −0.90% * (0.37%) | −0.89% * (0.37%) |
| Gender: Male | 26.64% ** (8.18%) | 26.64% ** (8.17%) | −7.17% (5.05%) | −7.51% (5.04%) | 19.07% ** (5.57%) | 19.28% ** (5.57%) |
| Age | −1.00% *** (0.27%) | −1.00% *** (0.27%) | 0.40% * (0.18%) | 0.41% * (0.18%) | −0.72% *** (0.19%) | −0.72% *** (0.19%) |
| Comorbidities 1 | 1.03% ** (0.35%) | 1.04% ** (0.35%) | 1.16% *** (0.23%) | 1.15% *** (0.23%) | −0.56% * (0.26%) | −0.57% * (0.26%) |
| IV Used | Yes | No | Yes | No | Yes | No |
| Naïve OLS | No | Yes | No | Yes | No | Yes |
* p < 0.05; ** p < 0.01; *** p < 0.001 Coefficients represent the percent change of the odds that a patient enters an unhealthy vital sign health state as a result of a one minute delay in medication delivery from the medication group in consideration. The numbers represent the coefficient estimates; the numbers in parentheses represent standard errors on these estimates. Statistical significance is shown using asterisks. Row labels represent the variable being estimated. 1 Comorbidities are measured as a count variable of the number of unique diagnosis codes during the patient’s ICU stay.